Johnson & Johnson has filed a Biologics License Application with the U.S. Food and Drug Administration for a fixed combination of amivantamab and recombinant human hyaluronidase intended

SpineThera, Inc., a company specializing in long-acting injectable technologies, has announced a new partnership with Mayo Clinic to develop treatments aimed at improving outcomes for those with substance abuse disorders.

UMC Utrecht has started its initial enrollment for a study focused on discovering biomarkers for Amyotrophic Lateral Sclerosis. This research, led by Professor Dr. Leonard van den Berg

Enveda Biosciences, a biotechnology firm that uses artificial intelligence to develop new medicines from natural sources, has raised $55 million in its latest funding round, adding to the $119 million previously secured in Series B

CyanVac LLC, a biotechnology firm focused on clinical-stage development, has secured funding through Project NextGen to advance a Phase 2b clinical trial of its COVID-19 vaccine candidate, CVXGA.

Renova Therapeutics, a biotech company focused on creating gene therapy solutions for cardiovascular and metabolic conditions, has disclosed its strategic plans to expand the therapeutic use of its gene therapies

Zumutor Biologics Inc., based in Boston and specializing in clinical-stage oncology, has commenced a Phase 1 clinical trial with ZM008. This trial will evaluate ZM008 both as a monotherapy

Flagship Pioneering and ProFound™ Therapeutics, both founded by Flagship, have announced a collaboration aimed at pioneering new treatments for obesity. This partnership represents the first initiative

Cyrus Biotechnology, Inc., based in Seattle, is spinning off its software and services division, Levitate Bio, to introduce the Cyrus platform to the broader biopharma sector. This move supports the development of its IdeS IgG degrading

Medable Inc., a leader in technology for modern clinical trials, has released important findings from a study conducted by the Partnership for Advancing Clinical Trials (PACT) consortium in partnership with the Tufts Center for the Study of Drug Development